CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Operating expenses:
Research and development		$ 61,826	$ 137,234	$ 253,741	$ 594,683
General and administrative		833,304	869,237	3,325,649	3,650,920
Total operating expenses		895,130	1,006,471	3,579,390	4,245,603
Loss before other income (expense)		(895,130)	(1,006,471)	(3,579,390)	(4,245,603)
Interest income, net		21,663	34,350	38,565	133,759
Loss from continuing operations		(873,467)	(972,121)	(3,540,825)	(4,111,844)
Net loss		$ (873,467)	$ (972,121)	$ (3,540,825)	$ (4,111,844)
Loss per common share, basic ( in dollar per share)	[1]	$ (1.81)	$ (11.38)	$ (14.35)	$ (76.96)
Loss per common share, diluted ( in dollar per share)	[1]	$ (1.81)	$ (11.38)	$ (14.35)	$ (76.96)
Weighted average number of common shares outstanding, basic (in shares)	[1]	481,587	85,458	246,741	53,426
Weighted average number of common shares outstanding, diluted (in shares)	[1]	481,587	85,458	246,741	53,426

[1] Shares and per share amounts have been recast to reflect the 1-for-8 and 1-for-15 reverse stock split effected in June 14, 2024 and August 15, 2025, respectively.